PositiveID

ExcitePCR's technology detects pathogens in 30 minutes or less using a backpack-sized device, integrating sample prep with PCR and RIF technology in a disposable cartridge.

The subsidiary, called ExcitePCR, will own and complete development of the company's Firefly Dx real-time PCR breadboard prototype pathogen detection system.

The company's revenues were primarily derived from a deferred license fee from Boeing, with the remainder coming from the operations of two recent acquisitions.

Proceeds will go toward the further development and field testing of the Firefly DX system and for general working capital. 

The partners will evaluate GenArraytion's MultiFlex assays for clinical, veterinary, food-and water-borne, and weaponized pathogens.

The company's chairman and CEO said that PositiveID has a sizeable backlog and pipeline of revenue opportunities for 2015. 

PositiveID will issue $4 million in senior secured convertible promissory notes to institutional investor Dominion Capital, the firm announced today.

NEW YORK (GenomeWeb) – PositiveID today announced an agreement with the US Special Operations Command Research, Development, and Acquisition Center to further develop military applications for the company's real-time PCR pathogen detection system, Firefly Dx.

NEW YORK (GenomeWeb) — PositiveID and Ensco have been awarded a SenseNet Program contract for an undisclosed amount from the US Department of the Interior on behalf of the US Department of Homeland Security Science and Technology Directorate, Positive ID said today.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.